Assessment of External Beam Radiation Technology for Dose Escalation and Normal Tissue Protection in the Treatment of Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 3, 2008, Pages 671-677

  D'Ambrosio, David J ^a   Pollack, Alan ^a   Harris, Eleanor E R ^b   Price Jr , Robert A ^a   Verhey, Lynn J ^c   Roach III, Mack ^c   Demanes, D Jeffrey ^d   Steinberg, Michael L ^e   Potters, Louis ^f   Wallner, Paul E ^g   Konski, Andre ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d California Endocurietherapy Cancer Center   (United States)

^e Santa Monica Hematology Oncology Consultant   (United States)

^f SOUTH NASSAU COMMUNITIES HOSPITAL   (United States)

^g 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Biochemical failure; Dose escalation; IMRT; Normal tissue toxicity; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COST BENEFIT ANALYSIS; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW ENERGY RADIATION; METASTASIS; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RADIATION RESPONSE; RETROSPECTIVE STUDY; SEXUAL FUNCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

HUMANS; INTESTINES; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME; URINARY BLADDER;

EID: 38849095288     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.034     Document Type: Article

References (63)

1. *Stat Database: Incidence and mortality. Available at: http://seer.cancer.gov/. Accessed May 4, 2007.
2. Fletcher G.H., and Shukovsky L.J. The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 56 (1975) 383-400
3. Pollack A., Hanlon A.L., Horwitz E.M., et al. Prostate cancer radiotherapy dose response: An update of the fox chase experience. J Urol 171 (2004) 1132-1136
4. Jacob R., Hanlon A.L., Horwitz E.M., et al. Role of prostate dose escalation in patients with >15% risk of pelvic lymph-node involvement. Int J Radiat Oncol Biol Phys 57 (2003) S150
5. Morgan P.B., Hanlon A.L., Horwitz E.M., et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1074-1081
6. Hanlon A.L., Horwitz E.M., Buyyounouski M.K., et al. 2244: Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis. Int J Radiat Oncol Biol Phys 66 (2006) S346-S347
7. Jacob R., Hanlon A.L., Horwitz E.M., et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100 (2004) 538-543
8. Nguyen K.H., Horwitz E.M., Hanlon A.L., et al. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?. Int J Radiat Oncol Biol Phys 57 (2003) 377-383
9. Pollack A., Smith L.G., and von Eschenbach A.C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Red J 48 (2000) 507-512
10. Cheung R., Tucker S.L., Dong L., et al. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 1234-1240
11. Cheung R., Tucker S.L., Lee A.K., et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 993-1002
12. Vora S.A., Wong W.W., Schild S.E., et al. 2288: Analysis of biochemical control and prognostic factors in patients treated with either low dose 3-dimensional conformal radiation therapy or high dose IMRT for localized prostate cancer. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S370
13. Symon Z., Griffith K.A., McLaughlin P.W., et al. Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 57 (2003) 384-390
14. Karlsdottir A., Paul Muren L., Wentzel-Larsen T., et al. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncol 45 (2006) 454-462
15. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
16. Mackley H.B., Reddy C.A., Reuther A.M., et al. 2218: Relapse-free survival with escalating external beam radiation doses in the treatment of localized prostate cancer: 74 Gy at 2 Gy, 78 Gy at 2 Gy, and hypofractionated 70 Gy at 2.5 Gy per fraction. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S331
17. Zelefsky M.J., Hunt M.A., Fuks Z., et al. 16: Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S9
18. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
19. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
20. Kupelian P., Kuban D., Thames H., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
21. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
22. Pisansky T.M., Thames H.D., Levy L.B., et al. Clinical outcomes and prognostic factors in 4839 patients treated with external radiotherapy for stage T1-T2 prostate cancer. [Abstract]. Int J Radiat Oncol Biol Phys 60 Suppl. (2004) S167
23. Bey P., Carrie C., Ginestet C., et al. French study of dose escalation from 66 to 80 GY with 3D-CRT in prostate cancer: results at 5 years. Int J Radiat Oncol Biol Phys 57 (2003) S272
24. Bey P., Carrie C., Beckendorf V., et al. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-Preliminary results. Red J 48 (2000) 513-517
25. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
26. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32 (1995) 3-12
27. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
28. Kuban D., Tucker S., Dong L., et al. 15: Long-term results of a randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) S8-S9
29. Pollack A., Zagars G.K., Antolak J.A., et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54 (2002) 677-685
30. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
31. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
32. Verhey L.J. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 9 (1999) 79-98
33. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1297-1308
34. Madsen B., Pham H., Hsi R.A., et al. Comparison of rectal dose volume histograms for definitive prostate radiotherapy among stereotactic radiotherapy, IMRT, and 3D-CRT techniques. [Abstract]. Int J Radiat Oncol Biol Phys 60 Suppl. (2004) S633
35. Tucker S.L., Dong L., Cheung R., et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 60 (2004) 1589-1601
36. Shahar K.H., McGary J.E., Mai W., et al. Retrospective analysis of late rectal bleeding in prostate cancer patients treated with intensity modulated radiotherapy (IMRT). [Abstract]. Int J Radiat Oncol Biol Phys 60 Suppl. (2004) S459
37. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 953-962
38. Shippy A.M., Hunt M.A., Yamada Y., et al. 58: Long-term toxicity outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) S34
39. Cahlon O., Zelefsky M., Shippy A., et al. 59: Intensity modulated radiation therapy to a dose of 86.4 gy for localized prostate cancer: toxicity data and preliminary biochemical outcomes. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S33-S33
40. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
41. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
42. Incrocci L., Slob A.K., and Levendag P.C. Sexual (dys)function after radiotherapy for prostate cancer: A review. Int J Radiat Oncol Biol Phys 52 (2002) 681-693
43. Su A.W., Gratzle J., Correa D., et al. 2294: Comparison of chronic GI and GU toxicity of patients with prostate cancer undergoing IMRT vs conventional radiotherapy using localized fields. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S374
44. Kirichenko A.V., Ruth K., Horwitz E.M., et al. 2209: Intensity modulated radiation therapy for prostate cancer: preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S326
45. Roach M., Winter K., Michalski J.M., et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 60 (2004) 1351-1356
46. Sethi A., Mohideen N., Leybovich L., et al. Role of IMRT in reducing penile doses in dose escalation for prostate cancer. Int J Radiat Oncol Biol Phys 55 (2003) 970-978
47. Buyyounouski M.K., Horwitz E.M., Uzzo R.G., et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1383-1391
48. Kao J., Turian J., Meyers A., et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol 77 (2004) 129-136
49. Buyyounouski M.K., Horwitz E.M., Price R.A., et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys 58 (2004) 743-749
50. Chao S.T., Reddy C.A., Thakkar V.V., et al. Impact of high-dose radiation on erectile function in patients treated with intensity-modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) S270-S271
51. D'Ambrosio D., Zelefsky M., Chan H., et al. Prognostic factors for maintained efficacy of Sildenafil citrate in the management of erectile dysfunction after radiotherapy for prostate cancer. [Abstract]. IInt J Radiat Oncol Biol Phys 57 Suppl. (2003) S274
52. Mangar S.A., Sydes M.R., Tucker H.L., et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol 80 (2006) 355-362
53. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54 (2002) 1036-1046
54. Ritter M.A., Forman J.D., Petereit D.G., et al. 19: Dose-per-fraction escalation for localized prostate cancer-A multi-institutional phase I/II Trial. Int J Radiat Oncol Biol Phys 66 (2006) S11-S11
55. Little D.J., Kuban D.A., Levy L.B., et al. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 62 (2003) 707-713
56. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1056-1065
57. Litwin M.S., Lubeck D.P., Henning J.M., et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 159 (1998) 1988-1992
58. Wilson L.S., Elkin E.P., Sadetsky N., et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109 (2007) 518-527
59. Bayoumi A.M., Brown A.D., and Garber A.M. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92 (2000) 1731-1739
60. Piper N.Y., Kusada L., Lance R., et al. Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis 5 (2002) 164-166
61. Stewart S.T., Lenert L., Bhatnagar V., et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care 43 (2005) 347-355
62. Konski A., Watkins-Bruner D., Feigenberg S., et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 408-415
63. Ruchlin H.S., and Pellissier J.M. An economic overview of prostate carcinoma. Cancer 92 (2001) 2796-2810